{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:52Z","timestamp":1790691412097,"version":"4.1.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Eisai Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>Our objective was to evaluate preferences associated with grade I\/II and grade III\/IV chemotherapy side effects among breast cancer patients receiving chemotherapy. We also assessed trade-offs that patients are willing to make between treatment side effects and the route and schedule of treatment administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>In this cross-sectional study, patients receiving chemotherapy for breast cancer completed a one-time Web survey. Conjoint analysis was used to elicit preferences for 17 grade I\/II and III\/IV side effects associated with available chemotherapies and regimens. In the analysis, the risk of each side effect was increased by 5%, holding all others constant, and the respective impact on patient preferences was identified.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>A total of 102 women participated (mean age 54 \u00b1 11). Among the grade I\/II side effects, a 5% reduction in the risk of sensory neuropathy, nausea, and motor neuropathy had the highest impact on preferences. Among grade III\/IV side effects, motor neuropathy, nausea\/vomiting, and myalgia made the most difference. An oral twice-daily regimen was most preferred; however, patients were willing to receive an intravenous regimen relative to oral to avoid an increased risk of 5% in the majority of side effects. Avoiding an increased chance of grade III\/IV motor neuropathy was associated with willingness to tolerate one of the least preferred administration schedules.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>This study identified relative preferences among both mild\/moderate to severe side effects from the patient perspective. Patients appear to be willing to make trade-offs between side effects and different regimens. These findings may help to inform medical decision-making processes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2013-0359","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T03:37:07Z","timestamp":1390966627000},"page":"127-134","source":"Crossref","is-referenced-by-count":65,"title":["Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects"],"prefix":"10.1093","volume":"19","author":[{"given":"Kathleen","family":"Beusterien","sequence":"first","affiliation":[{"name":"Outcomes Research Strategies in Health, Washington, D.C., USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Grinspan","sequence":"additional","affiliation":[{"name":"Oxford Outcomes, an ICON plc Company, Bethesda, Maryland, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Kuchuk","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Mazzarello","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Gertler","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Royal Victoria Hospital, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vandermeer","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Ottawa Hospital Cancer Centre, and Department of Medicine, University of Ottawa, Ottawa, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"2021122308533025800_B1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1634\/theoncologist.8-6-514","article-title":"Goals and objectives in the management of metastatic breast cancer","volume":"8","author":"Chung","year":"2003","journal-title":"The Oncologist"},{"key":"2021122308533025800_B2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2354.1999.00152.x","article-title":"A patient preference study comparing raltitrexed (\u2018Tomudex\u2019) and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: Influence of side-effects and administration attributes","volume":"8","author":"Young","year":"1999","journal-title":"Eur J Cancer Care"},{"key":"2021122308533025800_B3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: A cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2021122308533025800_B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","article-title":"Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer"},{"key":"2021122308533025800_B5","first-page":"149","article-title":"Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer","volume":"3","author":"Dubey","year":"2005","journal-title":"J Support Oncol"},{"key":"2021122308533025800_B6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"2021122308533025800_B7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/002224299005400402","article-title":"Conjoint analysis in marketing: New developments with implications for research and practice","volume":"54","author":"Green","year":"1990","journal-title":"J Mark"},{"key":"2021122308533025800_B8","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"Ryan","year":"2000","journal-title":"BMJ"},{"key":"2021122308533025800_B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"2021122308533025800_B10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"2021122308533025800_B11","volume-title":"Sawtooth Software. ACA\/Web Technical Paper"},{"key":"2021122308533025800_B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5050","article-title":"Eliciting public preferences for healthcare: A systematic review of techniques","volume":"5","author":"Ryan","year":"2001","journal-title":"Health Technol Assess"},{"key":"2021122308533025800_B13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/IJWH.S31331","article-title":"Patient preferences for chemotherapies used in breast cancer","volume":"4","author":"Beusterien","year":"2012","journal-title":"Int J Womens Health"},{"key":"2021122308533025800_B14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3747\/co.v17i4.562","article-title":"Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: A retrospective, outcomes-based survey","volume":"17","author":"Saibil","year":"2010","journal-title":"Curr Oncol"},{"key":"2021122308533025800_B15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.lungcan.2012.01.016","article-title":"Patients\u2019 preferences for treatment outcomes for advanced non-small cell lung cancer: A conjoint analysis","volume":"77","author":"Bridges","year":"2012","journal-title":"Lung Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/2\/127\/41867813\/oncolo_19_2_127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/2\/127\/41867813\/oncolo_19_2_127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T01:35:36Z","timestamp":1640309736000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/2\/127\/6399270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,28]]},"published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0359","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,2,1]]},"published":{"date-parts":[[2014,1,28]]}}}